My overall review: Wegovy is a highly effective, evidence-based weight-management medicine, especially when obesity is creating other health risks. But it is usually a long-term treatment and needs medical supervision.
- It contains semaglutide, a GLP-1 medicine that reduces appetite and slows stomach emptying.
- In a major trial, patients without diabetes lost about 15% of their starting weight on average over 68 weeks, versus about 2.4% with placebo. Individual results vary considerably. NEJM STEP-1 trial
- In people with established cardiovascular disease and overweight/obesity, serious cardiovascular events occurred in 6.5% with Wegovy versus 8% with placebo. FDA cardiovascular approval
- It may improve blood pressure, blood sugar and some cholesterol measurements as weight